SELLAS Life Sciences Group, Inc.

As of June 30, 2026, SELLAS Life Sciences Group, Inc. carries a market capitalization of 2.66B, placing it among publicly traded companies globally. Its enterprise value stands at 2.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SELLAS Life Sciences Group, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, SELLAS Life Sciences Group, Inc. has 201.92M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, SELLAS Life Sciences Group, Inc. maintains a current ratio of 18.83, meaning it holds 18.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, SELLAS Life Sciences Group, Inc. posted a negative return on equity (ROE) of -39.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -36.54, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 13.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, SELLAS Life Sciences Group, Inc.'s stock has gained approximately 536.08% over the past 52 weeks. The 50-day moving average sits at 10.90, while the 200-day moving average is 7.35.

Over the twelve months ended June 30, 2026, SELLAS Life Sciences Group, Inc. generated - - in revenue and converted that into -28.41M in net income, yielding earnings per share of -0.18. EBITDA reached -30.83M, while operating income came in at -30.83M.

As of June 30, 2026, SELLAS Life Sciences Group, Inc. holds 121.09M in cash and equivalents against 645,096.10 in total debt, resulting in a net debt position of -121.09M. Total book value stands at 120.49M, with working capital of 118.11M providing operational flexibility.

SELLAS Life Sciences Group, Inc. produced -24.88M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.66, meaning SELLAS Life Sciences Group, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SELLAS Life Sciences Group, Inc.'s most recent stock split took place on November 8, 2019 with a 50:1 split ratio.

As of June 30, 2026, SELLAS Life Sciences Group, Inc. has an Altman Z-Score of 233.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.